The most significant data comes from the REDEFINE trials, evaluating the co-administration of Cagrilintide and Semaglutide These findings highlight the synergistic potential of combining the amylin pathway (Cagrilintide) and the GLP-1 pathway (Semaglutide) to achieve superior metabolic and weight loss outcomes compared to either agent alone
It means the decision should be made through individual clinical judgement, not a simple online checkout
This could make it more affordable and easier to access, as it wouldnt face the same supply shortages that sometimes affect injectable treatments
[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Oestreicher J, Morgan B
Still, Judge Marston determined that a gastric emptying study, via scintigraphy, breath test, or wireless motility capsule, is necessary to ensure reliability